Reduction of Benzodiazepine Use in Patients with Prescribed Therapeutic Cannabis (STUDY 2019)

  • Reduction of Benzodiazepine Use in Patients with Prescribed Therapeutic Cannabis (STUDY 2019)

The use of benzodiazepines is associated with a large number of side effects. Is it possible to reduce their use with medical cannabis? The new study focuses on this issue.

Extract from the study

Study background:

Benzodiazepines belong to the group of medicines with sedative effects. Their use is most common in people suffering from anxiety and other neurological problems. These drugs are associated with various side effects.

This observational study focuses on investigating the reduction in benzodiazepine use in prescription cannabis users.

Methods used:

146 patients using cannabis who took benzodiazepines at the start of “cannabis” therapy participated in the retrospective analysis. The average age was 47 years, women prevailed in 61% and 54% reported that they had already used cannabis.

This data is part of the database and was collected by Canabo Medical.

Results:

At the end of the two-month course, 30.1% of patients with benzodiazepines ended up. After another two months, 65 (44.5%) patients discontinued benzodiazepine treatment. At the end of the 6-month treatment period, a total of 66 (45.2%) patients decided to discontinue benzodiazepines.

Results:
Of the 146 patients who underwent cannabis therapy, 45.2% of patients successfully discontinued benzodiazepine treatment. This research needs further examination to determine the effects of therapeutic cannabis use. In addition, the potential risks and the relationship between cannabis and benzodiazepines need to be addressed.


Key words: benzodiazepines, prescription, discontinuation, therapeutic cannabis


Authors of the study: Chad Purcell, Andrew Davis, Nico Moolman, S. Mark Taylor.
You can read more of this study at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757237/. The whole study is in English.

Photo source: unsplash.com (by Ben Blennerhassett)